Compile Data Set for Download or QSAR
Report error Found 3024 Enz. Inhib. hit(s) with Target = 'GTPase KRas [G12V]'
TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706700(US20240383922, Example 22-2)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706571(US20240383915, Example 100a)
Affinity DataIC50: 0.0300nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706507(US20240383915, Example 48)
Affinity DataIC50: 0.0400nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706612(US20240383915, Example 133c)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706594(US20240383915, Example 119)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706535(US20240383915, Example 75a)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706551(US20240383915, Example 88)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706526(US20240383915, Example 66a)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706670(US20240383922, Example 6-23)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706539(US20240383915, Example 78)
Affinity DataIC50: 0.0600nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706626(US20240383915, Example 147)
Affinity DataIC50: 0.0600nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706593(US20240383915, Example 118)
Affinity DataIC50: 0.0600nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706609(US20240383915, Example 130a)
Affinity DataIC50: 0.0600nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706573(US20240383915, Example 101)
Affinity DataIC50: 0.0600nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706582(US20240383915, Example 108a)
Affinity DataIC50: 0.0600nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM717620(US20250034173, Example 11)
Affinity DataKd:  0.0670nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706542(US20240383915, Example 81)
Affinity DataIC50: 0.0670nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706604(US20240383915, Example 127)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706562(US20240383915, Example 94)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706595(US20240383915, Example 120a)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706561(US20240383915, Example 93d)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706569(US20240383915, Example 99a)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706560(US20240383915, Example 93c)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706616(US20240383915, Example 137)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706556(US20240383915, Example 92a)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706597(US20240383915, Example 121)
Affinity DataIC50: 0.0700nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM717622(US20250034173, Example 13)
Affinity DataKd:  0.0720nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706591(US20240383915, Example 116)
Affinity DataIC50: 0.0740nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706552(US20240383915, Example 89)
Affinity DataIC50: 0.0750nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706596(US20240383915, Example 120b)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706570(US20240383915, Example 99b)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706579(US20240383915, Example 105a)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706618(US20240383915, Example 139)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706592(US20240383915, Example 117)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706566(US20240383915, Example 97)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706647(US20240383915, Example 175)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706565(US20240383915, Example 96)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706614(US20240383915, Example 135)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706613(US20240383915, Example 134)
Affinity DataIC50: 0.0800nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706658(US20240383922, Example 6-11)
Affinity DataIC50: 0.0810nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706549(US20240383915, Example 87a)
Affinity DataIC50: 0.0870nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706550(US20240383915, Example 87b)
Affinity DataIC50: 0.0890nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706547(US20240383915, Example 85)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706563(US20240383915, Example 95a)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706587(US20240383915, Example 113a)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706661(US20240383922, Example 6-14)
Affinity DataIC50: 0.0900nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706536(US20240383915, Example 76a)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706534(US20240383915, Example 74a)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706558(US20240383915, Example 93a)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706605(US20240383915, Example 128a)
Affinity DataIC50: 0.0900nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

Displayed 1 to 50 (of 3024 total ) | Next | Last >>
Jump to: